Sarepta falls after halting three studies of Duchenne gene therapy

Shares of gene therapy maker Sarepta Therapeutics SRPT.O fall 4.2% to $56.17

Co says it temporarily halted three trials testing its gene therapy Elevidys for Duchenne Muscular Dystrophy, as EU regulators reviewed a death of a patient who had received its gene therapy last month

Co says an independent committee met on Thursday and concluded that the benefit-risk profile of the therapy "remains favorable to continue dosing in the paused clinical trials"

Says co and partner Roche ROG.S will submit this information at the request of EU regulators within a week

Up to last close, SRPT shares down 55.1% YTD